India Pharma Outlook Team | Tuesday, 16 December 2025
Lupin, a global pharmaceutical company, is making a substantial move towards sustainability. The Science Based Targets initiative (SBTi) certified its greenhouse gas reduction plan, and includes Scope 1, Scope 2, and Scope 3 emissions.
It implies that the plan of Lupin corresponds to the Paris Agreement ambition to reduce the warming to 1.5 o C and demonstrates that the company is responsible in the international pharmaceutical market.
The fact that Lupin is now one of the few companies whose entire SBTi validation is accepted to all the scopes of the emissions in less than one year after defining its targets speaks volumes. This demonstrates in the pharma industry that the companies feel more pressure to reduce the emission that they emit out of their supply chains without compromising on the large scale operation of the company and remaining in compliance.
Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation
Under its short-term goals, Lupin aims at reducing its Scope 1 and Scope 2 greenhouse gases by 42 per cent by fiscal year 2030, based on fiscal year 2023. It is also a promise by the company to cut Scope 3 by 61.07 by fiscal year 2033 with a fiscal year 2024 target. Such cuts will include the emissions of things they purchase, fuel and energy consumption, transportation, business travel, employee travel, products processing and utilization that they sell, and franchisee.
Commenting on the development, Ramesh Swaminathan, executive director, global CFO, and head of IT and API Plus SBU, Lupin, said, “The validation from SBTi underscores Lupin’s unwavering commitment to reducing greenhouse gas emissions through a rigorous, science-driven approach. By setting ambitious targets, we are embedding sustainability into both our financial and operational strategies.”
The Science Based Targets initiative (SBTi) independently evaluates corporate climate targets and sets best practices, making the Lupin SBTi validation a strong signal of credibility to investors, partners, and regulators across the pharmaceutical industry.
.jpg)
